NCT05311943

Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Treatment With Olverembatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Failed to at Least Two Previously Administered Second-generation Tyrosine Kinase Inhibitors: a Prospective, Single-arm Clinical Trial.

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Shenzhen Second People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to evaluate the efficacy and safety of olverembatinib(HQP1351) in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to at least two second-generation tyrosine kinase inhibitors. The efficacy of olverembatinib is determined by evaluating the major molecular responses(MMR) at the and of 12 months.

Conditions

• Olverembatinib
• Chronic Myeloid Leukemia, Chronic Phase
• Tyrosine Kinase Inhibitors

Interventions

Type	Name	Description
DRUG	olverembatinib	olverembatinib, 40mg, taken orally once every other day of a 28-day cycle

Timeline

• Start date: 2022-07-01
• Primary completion: 2024-06-30
• Completion: 2025-06-30
• First posted: 2022-04-05
• Last updated: 2022-07-29

Locations

1 site across 1 country: China